Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

BACKGROUND: The androgen receptor (AR) is a pivotal drug target for the treatment of prostate cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR antagonists, such as hydroxyflutamide, bicalutamide, and enzalutamide, target the androgen binding site of the rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lallous, Nada, Volik, Stanislav V., Awrey, Shannon, Leblanc, Eric, Tse, Ronnie, Murillo, Josef, Singh, Kriti, Azad, Arun A., Wyatt, Alexander W., LeBihan, Stephane, Chi, Kim N., Gleave, Martin E., Rennie, Paul S., Collins, Colin C., Cherkasov, Artem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729137/
https://www.ncbi.nlm.nih.gov/pubmed/26813233
http://dx.doi.org/10.1186/s13059-015-0864-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729137/
https://www.ncbi.nlm.nih.gov/pubmed/26813233
http://dx.doi.org/10.1186/s13059-015-0864-1

Ejemplares similares